Boston Scientific Corp Net Assets
Boston Scientific Corp net assets. Based on the latest financial reports, Boston Scientific Corp (BSX) has net assets worth $26.10 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($44.35 Billion) and total liabilities ($18.25 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See BSX net asset quality score to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $26.10 Billion |
| % of Total Assets | 58.86% |
| Annual Growth Rate | 17.91% |
| 5-Year Change | 47.22% |
| 10-Year Change | 263.46% |
| Growth Volatility | 57.4 |
Net Assets of Boston Scientific Corp (1991–2025)
Net assets of Boston Scientific Corp from 1991 to 2025. This chart illustrates how Boston Scientific Corp's net assets have evolved over time, based on quarterly financial data. Also explore Boston Scientific Corp (BSX) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for Boston Scientific Corp (1991–2025)
The table below shows the annual net assets of Boston Scientific Corp from 1991 to 2025. For live market cap and overall valuation, see market value of Boston Scientific Corp.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $24.47 Billion | +11.22% |
| 2024-12-31 | $22.00 Billion | +12.66% |
| 2023-12-31 | $19.53 Billion | +11.13% |
| 2022-12-31 | $17.57 Billion | +5.72% |
| 2021-12-31 | $16.62 Billion | +8.46% |
| 2020-12-31 | $15.33 Billion | +10.45% |
| 2019-12-31 | $13.88 Billion | +59.05% |
| 2018-12-31 | $8.72 Billion | +24.45% |
| 2017-12-31 | $7.01 Billion | +4.13% |
| 2016-12-31 | $6.73 Billion | +6.53% |
| 2015-12-31 | $6.32 Billion | -7.64% |
| 2014-12-31 | $6.84 Billion | +4.65% |
| 2013-12-31 | $6.54 Billion | -4.82% |
| 2012-12-31 | $6.87 Billion | -39.49% |
| 2011-12-31 | $11.35 Billion | +0.50% |
| 2010-12-31 | $11.30 Billion | -8.17% |
| 2009-12-31 | $12.30 Billion | -6.37% |
| 2008-12-31 | $13.14 Billion | -12.98% |
| 2007-12-31 | $15.10 Billion | -1.31% |
| 2006-12-31 | $15.30 Billion | +257.26% |
| 2005-12-31 | $4.28 Billion | +6.39% |
| 2004-12-31 | $4.03 Billion | +40.64% |
| 2003-12-31 | $2.86 Billion | +16.01% |
| 2002-12-31 | $2.47 Billion | +22.43% |
| 2001-12-31 | $2.02 Billion | +4.13% |
| 2000-12-31 | $1.94 Billion | +12.24% |
| 1999-12-31 | $1.72 Billion | +109.96% |
| 1998-12-31 | $821.10 Million | -16.74% |
| 1997-12-31 | $986.20 Million | +7.63% |
| 1996-12-31 | $916.30 Million | +21.69% |
| 1995-12-31 | $753.00 Million | +121.47% |
| 1994-12-31 | $340.00 Million | +37.82% |
| 1993-12-31 | $246.70 Million | -0.96% |
| 1992-12-31 | $249.10 Million | +175.86% |
| 1991-12-31 | $90.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Boston Scientific Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8032.8% over the analyzed period, indicating profitable operations and earnings retention.
Boston Scientific Corp Net Assets Breakdown (December 2025)
Boston Scientific Corp net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $5.57 Billion | 22.99% |
| Common Stock | $17.00 Million | 0.07% |
| Other Comprehensive Income | $-610.00 Million | -2.52% |
| Other Components | $19.25 Billion | 79.46% |
| Total Equity | $24.23 Billion | 100.00% |
Boston Scientific Corp Competitors by Market Cap
The table below lists competitors of Boston Scientific Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Macquarie Group Ltd
AU:MQG
|
$67.02 Billion |
|
Natwest Group PLC
NYSE:NWG
|
$67.14 Billion |
|
NETEASE INC. O.N.
F:4Y01
|
$67.40 Billion |
|
ESSILORLUXOTTICA 1/2/O.N.
F:ESLC
|
$67.43 Billion |
|
Barclays PLC
F:BCY2
|
$66.81 Billion |
|
Atlas Copco AB Series A
ST:ATCO-A
|
$66.66 Billion |
|
Energy Transfer LP
NYSE:ET
|
$66.55 Billion |
|
TC Energy Corp
TO:TRP
|
$66.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Boston Scientific Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 21,770,000,000 to 24,233,000,000, a change of 2,463,000,000 (11.3%).
- Net income of 2,886,000,000 contributed positively to equity growth.
- Share repurchases of 282,000,000 reduced equity.
- Other comprehensive income decreased equity by 885,000,000.
- Other factors increased equity by 744,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.89 Billion | +11.91% |
| Share Repurchases | $282.00 Million | -1.16% |
| Other Comprehensive Income | $-885.00 Million | -3.65% |
| Other Changes | $744.00 Million | +3.07% |
| Total Change | $- | 11.31% |
Book Value vs Market Value Analysis
This analysis compares Boston Scientific Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.78x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 189.62x to 2.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1991-12-31 | $0.24 | $45.06 | x |
| 1992-12-31 | $0.64 | $45.06 | x |
| 1993-12-31 | $0.62 | $45.06 | x |
| 1994-12-31 | $0.81 | $45.06 | x |
| 1995-12-31 | $1.02 | $45.06 | x |
| 1996-12-31 | $1.15 | $45.06 | x |
| 1997-12-31 | $1.23 | $45.06 | x |
| 1998-12-31 | $1.06 | $45.06 | x |
| 1999-12-31 | $2.09 | $45.06 | x |
| 2000-12-31 | $2.36 | $45.06 | x |
| 2001-12-31 | $2.43 | $45.06 | x |
| 2002-12-31 | $2.98 | $45.06 | x |
| 2003-12-31 | $3.40 | $45.06 | x |
| 2004-12-31 | $4.70 | $45.06 | x |
| 2005-12-31 | $5.11 | $45.06 | x |
| 2006-12-31 | $12.01 | $45.06 | x |
| 2007-12-31 | $10.15 | $45.06 | x |
| 2008-12-31 | $8.77 | $45.06 | x |
| 2009-12-31 | $8.16 | $45.06 | x |
| 2010-12-31 | $7.44 | $45.06 | x |
| 2011-12-31 | $7.47 | $45.06 | x |
| 2012-12-31 | $4.88 | $45.06 | x |
| 2013-12-31 | $4.88 | $45.06 | x |
| 2014-12-31 | $5.08 | $45.06 | x |
| 2015-12-31 | $4.71 | $45.06 | x |
| 2016-12-31 | $4.89 | $45.06 | x |
| 2017-12-31 | $5.03 | $45.06 | x |
| 2018-12-31 | $6.23 | $45.06 | x |
| 2019-12-31 | $9.84 | $45.06 | x |
| 2020-12-31 | $10.82 | $45.06 | x |
| 2021-12-31 | $11.59 | $45.06 | x |
| 2022-12-31 | $12.21 | $45.06 | x |
| 2023-12-31 | $13.18 | $45.06 | x |
| 2024-12-31 | $14.65 | $45.06 | x |
| 2025-12-31 | $16.21 | $45.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Boston Scientific Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.91%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.38%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.80x
- Recent ROE (11.91%) is above the historical average (5.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1991 | 46.29% | 18.17% | 1.67x | 1.52x | $32.77 Million |
| 1992 | 22.72% | 17.96% | 1.05x | 1.20x | $31.69 Million |
| 1993 | 28.25% | 18.34% | 1.18x | 1.31x | $45.03 Million |
| 1994 | 23.44% | 17.75% | 1.04x | 1.27x | $45.70 Million |
| 1995 | 1.06% | 0.72% | 1.03x | 1.43x | $-67.30 Million |
| 1996 | 18.24% | 11.43% | 0.97x | 1.65x | $75.47 Million |
| 1997 | 14.12% | 7.44% | 0.95x | 2.00x | $40.68 Million |
| 1998 | -32.20% | -11.84% | 0.57x | 4.74x | $-346.51 Million |
| 1999 | 21.52% | 13.05% | 0.80x | 2.07x | $198.60 Million |
| 2000 | 19.28% | 14.00% | 0.78x | 1.77x | $179.50 Million |
| 2001 | -2.68% | -2.02% | 0.67x | 1.97x | $-255.50 Million |
| 2002 | 15.12% | 12.78% | 0.66x | 1.80x | $126.30 Million |
| 2003 | 16.49% | 13.58% | 0.61x | 1.99x | $185.80 Million |
| 2004 | 26.39% | 18.88% | 0.69x | 2.03x | $659.50 Million |
| 2005 | 14.67% | 10.00% | 0.77x | 1.91x | $199.80 Million |
| 2006 | -23.38% | -45.74% | 0.25x | 2.03x | $-5.11 Billion |
| 2007 | -3.28% | -5.92% | 0.27x | 2.07x | $-2.00 Billion |
| 2008 | -15.50% | -25.29% | 0.30x | 2.06x | $-3.35 Billion |
| 2009 | -8.33% | -12.52% | 0.33x | 2.05x | $-2.26 Billion |
| 2010 | -9.43% | -13.64% | 0.35x | 1.96x | $-2.19 Billion |
| 2011 | 3.88% | 5.79% | 0.36x | 1.88x | $-694.30 Million |
| 2012 | -59.21% | -56.12% | 0.42x | 2.50x | $-4.75 Billion |
| 2013 | -1.85% | -1.69% | 0.43x | 2.56x | $-774.90 Million |
| 2014 | -1.74% | -1.61% | 0.44x | 2.46x | $-803.30 Million |
| 2015 | -3.78% | -3.20% | 0.41x | 2.87x | $-871.00 Million |
| 2016 | 5.15% | 4.14% | 0.46x | 2.69x | $-326.30 Million |
| 2017 | 1.48% | 1.15% | 0.48x | 2.72x | $-597.10 Million |
| 2018 | 19.15% | 17.01% | 0.47x | 2.41x | $798.50 Million |
| 2019 | 33.87% | 43.78% | 0.35x | 2.20x | $3.31 Billion |
| 2020 | -0.54% | -0.83% | 0.32x | 2.01x | $-1.61 Billion |
| 2021 | 6.26% | 8.75% | 0.37x | 1.94x | $-622.30 Million |
| 2022 | 3.97% | 5.50% | 0.39x | 1.85x | $-1.06 Billion |
| 2023 | 8.26% | 11.19% | 0.41x | 1.82x | $-335.20 Million |
| 2024 | 8.52% | 11.07% | 0.43x | 1.81x | $-323.00 Million |
| 2025 | 11.91% | 14.38% | 0.46x | 1.80x | $462.70 Million |
Industry Comparison
This section compares Boston Scientific Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,467,017,896
- Average return on equity (ROE) among peers: -49.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Boston Scientific Corp (BSX) | $26.10 Billion | 46.29% | 0.70x | $66.98 Billion |
| Abbott Laboratories (ABT) | $24.08 Billion | 18.37% | 0.83x | $179.28 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-132.02 Million | 0.00% | 0.00x | $2.72 Million |
| Aethlon Medical Inc (AEMD) | $-2.20 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $792.23 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.28 Million | -44.54% | 0.25x | $2.40 Million |
| Allurion Technologies, Inc. (ALUR) | $19.83K | -26.07% | 15.64x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $2.01 Million |
| Artivion Inc (AORT) | $300.73 Million | -4.93% | 1.64x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $63.86 Million | -18.63% | 0.16x | $105.31 Million |
About Boston Scientific Corp
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyG… Read more